<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275193</url>
  </required_header>
  <id_info>
    <org_study_id>Zishenqing</org_study_id>
    <nct_id>NCT04275193</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>The Safety and Efficacy of the Traditional Chinese Medicine Zishenqing in Subjects With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of the traditional chinese medicine Zishenqing
      in the treatment of active systemic lupus erythematosus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a multicenter, randomized, double-blind, placebo parallel controlled
      clinical trial with a course of 12 weeks.

        1. Multicenter: During the study period, it will be decided whether to increase the
           improvement progress of the research unit according to whether it will be difficult to
           join the group and the overall progress, so as to complete the clinical study on time in
           accordance with the research plan.

        2. Random scheme: In this study, a dynamic random variance minimization random scheme will
           be adopted. Considering the two influencing factors of SLEDAI score and complement
           level, the DAS for Interactive Web Response System(IWRS) will be used to calculate and
           distribute random numbers and dispensing drugs.

        3. Control drug: Placebo will be used as control in this trial.

        4. Blind method: The Zishenqing simulator will be prepared by double-blind design, the
           dosage form, appearance, size, color and smell will be consistent with the experimental
           drug, and the test process will be in a double-blind state.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lupus Quality of Life (LupusQoL)</measure>
    <time_frame>12weeks</time_frame>
    <description>Self reported the quality of life in patients with systemic lupus erythematosus.LupusQoL is made up of five parts((physical health, pain, planning, emotional health, and fatigue) and has a total of 34 questions.Each question is scored0-4,yielding a total between 0 and 136.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The 36-item shot form health survey(SF-36)</measure>
    <time_frame>12weeks</time_frame>
    <description>As a concise health questionnaire, SF-36 comprehensively summarizes the quality of life of the subjects from eight aspects: physiological function, physiological function, physical pain, general health status, energy, social function, emotional function and mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic lupus erythematosus disease activity index(SLEDAI)</measure>
    <time_frame>12weeks</time_frame>
    <description>SLEDAI scores are used to determine the activity of SLE.SLEDAI consists of 24 clinical and laboratory projects with different weights（0:no activity;1-5:mild activity;6-10:moderate activity;11-19:severe activity;≥20:extremely severe activity).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Zishenqing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zishenqing</intervention_name>
    <description>Zishenqing Granule</description>
    <arm_group_label>Zishenqing</arm_group_label>
    <other_name>Zishenqingqi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Granule manufactured to mimic Zishenqing(containing 10% composition)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo(for Zishenqing)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who qualify for the diagnosis of systemic lupus erythematosus according to
             the American college of rheumatology's 1997 revised classification criteria for
             systemic lupus erythematosus;

          2. For inpatient or out-patient with good compliance, sign the informed consent before
             the test;

          3. Sledai score during screening period≤10;

          4. Maintain a stable standard treatment regimen for at least 30 days before the first day
             (that is, the date of administration of the intervention drug). Standard treatment
             regimens refer to the stable use of any of the following (alone or in combination):
             corticosteroids, hydroxychloroquine, non-steroidal anti-inflammatory drugs, other
             immunosuppressants or immunomodulators (including azathioprine, mycophenolate ester,
             cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine);

        Exclusion Criteria:

          1. Severe lupus nephritis requiring hemodialysis or high-dose glucocorticoid treatment in
             the last 2 months;

          2. Central nervous system diseases (including epilepsy, psychosis, organic encephalopathy
             syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis)
             caused by SLE or non-SLE in the last 2 months;

          3. Patients with severe heart, liver and kidney diseases and disease history of important
             organs, blood and endocrine system;

             Evaluation criteria of severity:

               1. Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST)≥3 times the
                  upper limit of normal;

               2. Glomerular filtration rate(GFR)&lt;30ml/min;

               3. White Blood Cell(WBC)&lt;2.0×10^9/l;

               4. Platelet(PLT)&lt;50×10^9/l;

          4. Immunodeficiency, uncontrolled infection and active or recurrent peptic ulcer;

          5. Pregnant and lactating women;

          6. Anaphylaxis: allergic to traditional Chinese medicine;

          7. The investigator considered it inappropriate to participate in this study;

          8. Participate in other clinical trials during the screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangjing Lv, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huanru Qu, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhujing Zhu, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruru Guo, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhongping Xu, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianchun Mao, Master</last_name>
    <phone>+8618917763231</phone>
    <email>mjczyczx@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhujing Zhu, Ph.D</last_name>
    <phone>+8613816914874</phone>
    <email>zzj01@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianchun Mao, master</last_name>
      <phone>86-18917763231</phone>
      <email>mjcct2018@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>maojianchun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

